How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
Maersk raises 2026 outlook again as earnings surge
A.P. Moller-Maersk raised its full-year earnings outlook after second-quarter revenue climbed 20% year over year and EBITDA reached…
Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026
Novo Nordisk A/S Bagsværd, Denmark, 6 May 2026 – Financial report for the period 1 January 2026 to…
Maersk posts Q4 pre-tax loss, will cut 1,000 jobs
Maersk saw pre-tax earnings fall to a loss in the fourth quarter as downward pressure on freight rates…